Viveon Health Acquisition (NYSE:VHAQ – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.
This is a breakdown of current recommendations and price targets for Viveon Health Acquisition and Aurinia Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Viveon Health Acquisition||0||0||0||0||N/A|
Aurinia Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 71.57%. Given Aurinia Pharmaceuticals’ higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Viveon Health Acquisition.
Volatility and Risk
This table compares Viveon Health Acquisition and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Viveon Health Acquisition||N/A||N/A||N/A|
Insider and Institutional Ownership
17.5% of Viveon Health Acquisition shares are owned by institutional investors. Comparatively, 39.6% of Aurinia Pharmaceuticals shares are owned by institutional investors. 73.2% of Viveon Health Acquisition shares are owned by insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Viveon Health Acquisition and Aurinia Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Viveon Health Acquisition||N/A||N/A||-$490,000.00||N/A||N/A|
|Aurinia Pharmaceuticals||$134.03 million||8.74||-$108.18 million||($0.53)||-15.40|
Viveon Health Acquisition has higher earnings, but lower revenue than Aurinia Pharmaceuticals.
About Viveon Health Acquisition
Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Receive News & Ratings for Viveon Health Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveon Health Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.